Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10457914 | 1.00 | ADORA1 (0.51) | ADORA1MEN1KMT2AADORA3ADORA2A | |
| SCHEMBL10462621 | 0.87 | ADORA1 (0.49) | ADORA1MEN1KMT2AADORA3ADORA2A | |
| SCHEMBL10459531 | 0.87 | ADORA1 (0.49) | ADORA1MEN1KMT2AADORA3ADORA2A | |
| SCHEMBL10459533 | 0.86 | KDM4E (0.51) | ADORA1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL10462552 | 0.86 | KDM4E (0.51) | ADORA1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL10459461 | 0.84 | TYMP (0.48) | ADORA1 | |
| SCHEMBL10461147 | 0.84 | TYMP (0.48) | ADORA1 | |
| SCHEMBL2761074 | 0.82 | MEN1 (0.66) | ADORA1MEN1KMT2AADORA3ADORA2A | |
| SCHEMBL3500482 | 0.82 | MEN1 (0.66) | ADORA1MEN1KMT2AADORA3ADORA2A | |
| SCHEMBL3499233 | 0.80 | ADORA2A (0.64) | ADORA2AADORA2BPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597421-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180186826-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. | 2018-07-05 | — | — | US | disclosed |
| US-9896472-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20120289691-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2010034024-A2 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289691-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | NSUN2, SNRPB2, RNGTT | ADORA1 2593/4885MEN1 2627/4885KMT2A 1641/4885 |
| US-20180186826-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | NSUN2, RNGTT, RNMT | ADORA1 4025/4885MEN1 1325/4885KMT2A 1645/4885 |
| US-10597421-B2 | Protected monomer and method of final deprotection for RNA synthesis | NSUN2, RNGTT, RNMT | ADORA1 4025/4885MEN1 1325/4885KMT2A 1645/4885 |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | RNMT, RNGTT, NSUN2 | ADORA1 2120/4885MEN1 1340/4885KMT2A 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.